Furthermore, treatment with CLK2 inhibitor T-025 significantly reduces CLK-dependent phosphorylation, thus promoting exon-skipping events, inducing apoptosis, and suppressing growth in both AML MV-4-11 and patient-derived xenograft models [59]. The gene discussed is CLK1; the disease is acute myeloid leukemia.